335 related articles for article (PubMed ID: 31651174)
21. Contrasting Roles of the PD-1 Signaling Pathway in Dendritic Cell-Mediated Induction and Regulation of HIV-1-Specific Effector T Cell Functions.
Garcia-Bates TM; Palma ML; Shen C; Gambotto A; Macatangay BJC; Ferris RL; Rinaldo CR; Mailliard RB
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541848
[TBL] [Abstract][Full Text] [Related]
22. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
23. Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes.
Wu Y; Gu W; Li J; Chen C; Xu ZP
Nanomedicine (Lond); 2019 Apr; 14(8):955-967. PubMed ID: 30901292
[TBL] [Abstract][Full Text] [Related]
24. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
[TBL] [Abstract][Full Text] [Related]
25. Combined Inhibition of TGF-β Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models.
Sow HS; Ren J; Camps M; Ossendorp F; Ten Dijke P
Cells; 2019 Apr; 8(4):. PubMed ID: 30959852
[TBL] [Abstract][Full Text] [Related]
26. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells.
Barsoum IB; Smallwood CA; Siemens DR; Graham CH
Cancer Res; 2014 Feb; 74(3):665-74. PubMed ID: 24336068
[TBL] [Abstract][Full Text] [Related]
27. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
[TBL] [Abstract][Full Text] [Related]
28. COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes.
Cecil DL; Gad EA; Corulli LR; Drovetto N; Lubet RA; Disis ML
Cancer Prev Res (Phila); 2022 Apr; 15(4):225-231. PubMed ID: 34987061
[TBL] [Abstract][Full Text] [Related]
29. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes.
Sawada Y; Yoshikawa T; Shimomura M; Iwama T; Endo I; Nakatsura T
Int J Oncol; 2015 Jan; 46(1):28-36. PubMed ID: 25354479
[TBL] [Abstract][Full Text] [Related]
30. Stromal PD-1/PD-L1 Expression Predicts Outcome in Colon Cancer Patients.
Wyss J; Dislich B; Koelzer VH; Galván JA; Dawson H; Hädrich M; Inderbitzin D; Lugli A; Zlobec I; Berger MD
Clin Colorectal Cancer; 2019 Mar; 18(1):e20-e38. PubMed ID: 30389315
[TBL] [Abstract][Full Text] [Related]
31. Programmed death-1 pathway blockade produces a synergistic antitumor effect: combined application in ovarian cancer.
Zhu X; Lang J
J Gynecol Oncol; 2017 Sep; 28(5):e64. PubMed ID: 28657225
[TBL] [Abstract][Full Text] [Related]
32. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
33. Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Homet Moreno B; Zaretsky JM; Garcia-Diaz A; Tsoi J; Parisi G; Robert L; Meeth K; Ndoye A; Bosenberg M; Weeraratna AT; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Ribas A
Cancer Immunol Res; 2016 Oct; 4(10):845-857. PubMed ID: 27589875
[TBL] [Abstract][Full Text] [Related]
34. Antitumor Effect of Korean Red Ginseng through Blockade of PD-1/PD-L1 Interaction in a Humanized PD-L1 Knock-In MC38 Cancer Mouse Model.
Lee EJ; Yang JH; Yang HJ; Cho CK; Choi JG; Chung HS
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768213
[TBL] [Abstract][Full Text] [Related]
35. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
37. Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8
Li YM; Yu JM; Liu ZY; Yang HJ; Tang J; Chen ZN
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31627272
[TBL] [Abstract][Full Text] [Related]
38. Targeted Delivery of IL2 to the Tumor Stroma Potentiates the Action of Immune Checkpoint Inhibitors by Preferential Activation of NK and CD8
Hutmacher C; Gonzalo Núñez N; Liuzzi AR; Becher B; Neri D
Cancer Immunol Res; 2019 Apr; 7(4):572-583. PubMed ID: 30782667
[TBL] [Abstract][Full Text] [Related]
39. Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1-Independent Manner.
Long Y; Chen R; Yu X; Tong Y; Peng X; Li F; Hu C; Sun J; Gong L
Cancer Immunol Res; 2023 Feb; 11(2):241-260. PubMed ID: 36484740
[TBL] [Abstract][Full Text] [Related]
40. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
Lai Q; Wang H; Li A; Xu Y; Tang L; Chen Q; Zhang C; Gao Y; Song J; Du Z
Oncogene; 2018 Apr; 37(17):2302-2312. PubMed ID: 29422611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]